Skip to main content

Anti-inflammatory Molecules: Immune System Mediators

  • Chapter
  • First Online:
Bioresources and Bioprocess in Biotechnology

Abstract

Inflammation typifies the chief defensive mechanism against infection or injury. However, its obnoxious activation often elicits exaggerated immune response and the onset of clinically relevant detrimental responses. Suppression of inflammatory response by means of anti-inflammatory molecules is therefore weighed as a pivotal therapeutic solution to a wide range of diseases. The quest for newer and vital anti-inflammatory molecules has been considered as an active research vista for the development of potential drug candidates for a variety of pathological conditions. Inflammation and immune responses are inseparably linked in many instances, where the persisting inflammatory response serves as the key trigger for immune disorders. The immune system comprises immune cells and immunoglobulins, which are the major mediators of defensive response against obnoxious stimuli. Several anti-inflammatory molecules have been found to ameliorate immune reaction underlying many pathogenesis, via directly regulating production/function/activation of the prime components of the immune system and limit tissue damage. This chapter provides an insight into the ability of such anti-inflammatory molecules which target components of the immune system. The interplay of adaptive immunity and inflammatory mechanism in terms of chronic inflammatory disease pathogenesis is critically evaluated and demonstrated. An effort has been made to explain how this approach of inhibiting inflammatory targets qualifies as a potent therapeutic solution for immune disorders and transplant rejection. The emphasis is on identifying plausible anti-inflammatory agents targeting immune system mediators as a logical strategy for novel and efficient therapeutic interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Abramson S, Weissmann G (1981) The release of inflammatory mediators from neutrophils. Ric Clin Lab 11(2):91–99

    Google Scholar 

  • Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol 65:16–21

    CAS  Google Scholar 

  • Ballanti E, Perricone C, di Muzio G, Kroegler B, Chimenti MS, Graceffa D, Perricone R (2011) Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev 10:617–623

    Article  CAS  PubMed  Google Scholar 

  • Banyer JL, Hamilton NH, Ramshaw IA, Ramsay AJ (2000) Cytokines in innate and adaptive immunity. Rev Immunogenet 2:359–373

    CAS  PubMed  Google Scholar 

  • Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G (2007) Nonallergic angiodema: role of Bradykinin. Allergy 62(8):842–856

    Google Scholar 

  • Bell SJ, Kamm MA (2000) Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn’s disease. Aliment Pharmacol Ther 14:501–514

    Article  CAS  PubMed  Google Scholar 

  • Camp NJ, Cox A, di Giovine FS, McCabe D, Rich W, Duff GW (2005) Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun 6:467–471

    Article  CAS  PubMed  Google Scholar 

  • Capetti AF, Pocaterra D, Zucchi P, Carenzi L, Rizzardini G (2010) Anti-inflammatory effect of maraviroc in an HIV-infected patient with concomitant myositis: a case report. J Inter Ass Phys AIDS Care (Chicago) 9:201–202

    Google Scholar 

  • Castro Villegas Mdel C, Escudero Contreras A, Miranda Garcia MD, Collantes Estevez E (2012) How to optimize the anti-TNF alpha therapy in spondylitis? Reumatologia Clinica 8(1):S26–S31

    Article  PubMed  Google Scholar 

  • Chagnon M, Gentile J, Gladu M, Sirois P (1985) The mechanism of action of leukotrienes A4, C4 and D4 on human lung parenchyma in vitro. Lung 163:55–62

    Article  CAS  PubMed  Google Scholar 

  • Clark W, Jobanputra P, Barton P, Burls A (2004) The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Tech Assess 8:iii–iv, ix–x, 1–105

    Google Scholar 

  • Cook EB (2004) Tear cytokines in acute and chronic ocular allergic inflammation. Curr Opin Allergy Clin Immunol 4:441–445

    Article  CAS  PubMed  Google Scholar 

  • D’Ambrosio D, Panina-Bordignon P, Sinigaglia F (2003) Chemokine receptors in inflammation: an overview. J Immunol Methods 273:3–13

    Article  PubMed  Google Scholar 

  • de La Mata LJ, Gonzalez Crespo R, Maese Manzano J (2007) Treatment of rheumatoid arthritis with anakinra: a systematic review. Reumatol Clinica 3:153–158

    Article  Google Scholar 

  • Donnelly LE, Barnes PJ (2006) Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 27:546–553

    Article  CAS  PubMed  Google Scholar 

  • Du Buske LM (1996) Clinical comparison of histamine H1-receptor antagonist drugs. J Allergy Clin Immunol 98:S307–S318

    Article  PubMed  Google Scholar 

  • Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M (2011) New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 17:317–329

    Article  CAS  PubMed  Google Scholar 

  • El-Asrar AM (2012) Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthal 19:70–74

    Article  Google Scholar 

  • Elices MJ (2002) BX-471 Berlex. Curr Opin Investig Drugs 3:865–869

    Google Scholar 

  • Feghali CA, Wright TM (1997) Cytokines in acute and chronic inflammation. Front Biosci 2:d12–d26

    Article  CAS  PubMed  Google Scholar 

  • Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196

    Article  CAS  PubMed  Google Scholar 

  • Francisci D, Falcinelli E, Baroncelli S, Petito E, Cecchini E, Weimer LE, Floridia M, Gresele P, Baldelli F (2014) Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers. Scand J Infect Dis 46:466–470

    Article  CAS  PubMed  Google Scholar 

  • Furst R, Zundorf I (2014) Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediat Inflamm 2014:146832

    Article  Google Scholar 

  • Garcia-Marcos L, Schuster A (2001) Antileukotrienes in asthma: present situation. Expert Opin Pharmacother 2:441–466

    Article  CAS  PubMed  Google Scholar 

  • Greene ER, Huang S, Serhan CN, Panigrahy D (2011) Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat 96:27–36

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hampel U, Sesselmann S, Iserovich P, Sel S, Paulsen F, Sack R (2013) Chemokine and cytokine levels in osteoarthritis and rheumatoid arthritis synovial fluid. J Immunol Methods 396:134–139

    Article  CAS  PubMed  Google Scholar 

  • Handa P, Kowdley KV (2013) Chemokines: potent mediators of hepatic inflammation and fibrosis in chronic liver diseases. Ann Hepatol 13:152–154

    PubMed  Google Scholar 

  • Harter WG, Albrect H, Brady K, Caprathe B, Dunbar J, Gilmore J, Hays S, Kostlan CR, Lunney B, Walker N (2004) The design and synthesis of sulfonamides as caspase-1 inhibitors. Bioorg Med Chem Lett 14:809–812

    Article  CAS  PubMed  Google Scholar 

  • Haspel RL, Hillmen P (2008) Which patients with paroxysmal nocturnal hemoglobinuria (PNH) should be treated with eculizumab? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program 2008:35

    Google Scholar 

  • Hedqvist P, Dahlen SE, Palmertz U (1985) Leukotrienes as mediators of airway anaphylaxis. Adv Prostaglandin Thromboxane Leukot Res 15:345–348

    CAS  PubMed  Google Scholar 

  • Holers VM (2016) Targeting mechanisms at sites of complement activation for imaging and therapy. Immunobiology 221(6):726–732

    Article  CAS  PubMed  Google Scholar 

  • Jablonowski JA, Carruthers NI, Thurmond RL (2004) The histamine H4 receptor and potential therapeutic uses for H4 ligands. Mini-Rev Med Chem 4:993–1000

    Article  CAS  PubMed  Google Scholar 

  • Jang MH, Seoh JY, Miyasaka M (2006) Cytokines, chemokines, and their receptors: targets for immunomodulation. Conference report: international cytokine society conference 2005. J Leukoc Biol 80:217–219

    Article  CAS  PubMed  Google Scholar 

  • Kadioglu A, Sheldon P (1996) Adhesion of rheumatoid lymphocytes to mucosal endothelium: the gut revisited. Br J Rheumatol 35:218–225

    Article  CAS  PubMed  Google Scholar 

  • Keating GM (2013) Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs 73:2053–2066

    Article  CAS  PubMed  Google Scholar 

  • Kemp JP (2003) Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med 2:139–156

    Article  CAS  PubMed  Google Scholar 

  • Khanapure SP, Garvey DS, Janero DR, Letts LG (2007) Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem 7:311–340

    Article  CAS  PubMed  Google Scholar 

  • Kirschfink M (2001) Targeting complement in therapy. Immunol Rev 180:177–189

    Article  CAS  PubMed  Google Scholar 

  • Kiss R, Keseru GM (2012) Histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat 22:205–221

    Article  CAS  PubMed  Google Scholar 

  • Kiss R, Keseru GM (2014) Novel histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat 24:1185–1197

    Article  CAS  PubMed  Google Scholar 

  • Krystal AD, Richelson E, Roth T (2013) Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev 17:263–272

    Article  PubMed  Google Scholar 

  • Lam BK, Lee CY, Wong PY (1988) Phospholipase A2 (PLA2) releases lipoxins and leukotrienes from endogenous sources. Ann N Y Acad Sci 524:27–34

    Article  CAS  PubMed  Google Scholar 

  • Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366:1190–1199

    Article  CAS  PubMed  Google Scholar 

  • Martinel Lamas DJ, Rivera ES, Medina VA (2015) Histamine H4 receptor: insights into a potential therapeutic target in breast cancer. Front Biosci (Scholar Edition) 7:1–9

    Article  Google Scholar 

  • Martorana G, Casa A, Oliva L, Orlando A, Cottone M (2001) Treatment with chimeric monoclonal antitumor necrosis factor (infliximab) of patients with active steroid-dependent/resistant Crohn’s disease and fistulas. Recenti Prog Med 92:451–455

    CAS  PubMed  Google Scholar 

  • Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428–435

    Article  CAS  PubMed  Google Scholar 

  • Milligan CE, Prevette D, Yaginuma H, Homma S, Cardwell C, Fritz LC, Tomaselli KJ, Oppenheim RW, Schwartz LM (1995) Peptide inhibitors of the ICE protease family arrest programmed cell death of motoneurons in vivo and in vitro. Neuron 15:385–393

    Article  CAS  PubMed  Google Scholar 

  • Mollnes TE, Kirschfink M (2006) Strategies of therapeutic complement inhibition. Mol Immunol 43:107–121

    Article  CAS  PubMed  Google Scholar 

  • Montuschi P, Mondino C, Koch P, Barnes PJ, Ciabattoni G (2006) Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J Allergy Clin Immunol 118:347–353

    Article  CAS  PubMed  Google Scholar 

  • Morton AC, Arnold ND, Gunn J, Varcoe R, Francis SE, Dower SK, Crossman DC (2005) Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model. Cardiovasc Res 68:493–501

    Article  CAS  PubMed  Google Scholar 

  • Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14:155–174

    Article  CAS  PubMed  Google Scholar 

  • Mosesson MW, Siebenlist KR, Meh DA (2001) The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 936:11–30

    Google Scholar 

  • Navab M, Gharavi N, Watson AD (2008) Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab Care 11:459–464

    Article  CAS  PubMed  Google Scholar 

  • Ni J, Shu YY, Zhu YN, Fu YF, Tang W, Zhong XG, Wang H, Yang YF, Ren J, Wang MW, Zuo JP (2007) COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J Neuroimmunol 186:94–103

    Article  CAS  PubMed  Google Scholar 

  • Okamoto Y, Anan H, Nakai E, Morihira K, Yonetoku Y, Kurihara H, Sakashita H, Terai Y, Takeuchi M, Shibanuma T, Isomura Y (1999) Peptide based interleukin-1β-converting enzyme (ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the ICE-inhibitor complex. Chem Pharm Bull (Tokyo) 47:11–21

    Article  CAS  Google Scholar 

  • Owens T (2003) The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 16:259–265

    Article  PubMed  Google Scholar 

  • Parker CW (1982) Leukotrienes: their metabolism, structure, and role in allergic responses. Adv Prostaglandin Thromboxane Leukot Res 9:115–126

    CAS  PubMed  Google Scholar 

  • Patel AM, Moreland LW (2010) Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Design Develop Ther 4:263–278

    Article  Google Scholar 

  • Perricone C, De Carolis C, Giacomelli R, Greco E, Cipriani P, Ballanti E, Novelli L, Perricone R (2011) Inhibition of the complement system by glutathione: molecular mechanisms and potential therapeutic implications. Int J Immunopathol Pharmacol 24:63–68

    Article  CAS  PubMed  Google Scholar 

  • Petering H, Kohl J, Weyergraf A, Dulkys Y, Kimmig D, Smolarski R, Kapp A, Elsner J (2000) Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a. J Immunol 164:3783–3789

    Article  CAS  PubMed  Google Scholar 

  • Piatti G, Ceriotti L, Cavallaro G, Ambrosetti U, Mantovani M, Pistone A, Centanni S (2003) Effects of zafirlukast on bronchial asthma and allergic rhinitis. Pharmacol Res 47:541–547

    Article  CAS  PubMed  Google Scholar 

  • Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    Article  CAS  PubMed  Google Scholar 

  • Proudfoot AE, Power CA, Schwarz MK (2010) Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 19:345–355

    Article  CAS  PubMed  Google Scholar 

  • Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R (2001) ICE/caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs 10:1207–1209

    Article  CAS  PubMed  Google Scholar 

  • Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A (2013) A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 3:e003573

    Article  PubMed Central  PubMed  Google Scholar 

  • Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C (2012) In vivo roles of factor XII. Blood 120(22):4296–4303. doi:10.1182/blood-2012-07-292094

  • Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC (2005) The structure of interleukin-2 complexed with its alpha receptor. Science 308:1477–1480

    Article  CAS  PubMed  Google Scholar 

  • Rouzer CA, Marnett LJ (2009) Cyclooxygenases: structural and functional insights. J Lipid Res 50(Suppl):S29–S34

    PubMed Central  PubMed  Google Scholar 

  • Russo RC, Garcia CC, Teixeira MM, Amaral FA (2014) The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol 10:593–619

    Article  CAS  PubMed  Google Scholar 

  • Sarma JV, Ward PA (2011) The complement system. Cell Tissue Res 343:227–235

    Article  CAS  PubMed  Google Scholar 

  • Schreiber S (2007) Crohn’s disease–infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment. Dtsch Med Wochenschr 132:1770–1774

    Article  CAS  PubMed  Google Scholar 

  • Scully CC, Blakeney JS, Singh R, Hoang HN, Abbenante G, Reid RC, Fairlie DP (2010) Selective hexapeptide agonists and antagonists for human complement C3a receptor. J Med Chem 53:4938–4948

    Article  CAS  PubMed  Google Scholar 

  • Semple G, Ashworth DM, Batt AR, Baxter AJ, Benzies DW, Elliot LH, Evans DM, Franklin RJ, Hudson P, Jenkins PD et al (1998) Peptidomimetic aminomethylene ketone inhibitors of interleukin-1 beta-converting enzyme (ICE). Bioorg Med Chem Lett 8:959–964

    Article  CAS  PubMed  Google Scholar 

  • Shahripour AB, Plummer MS, Lunney EA, Albrecht HP, Hays SJ, Kostlan CR, Sawyer TK, Walker NP, Brady KD, Allen HJ, Talanian RV, Wong WW, Humblet C (2002) Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1). Bioorg Med Chem 10:31–40

    Article  CAS  PubMed  Google Scholar 

  • Smith LS, Nelson M, Dolder CR (2010) Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn’s disease. Ann Pharmacother 44:333–342

    Article  CAS  PubMed  Google Scholar 

  • Somm E, Cettour-Rose P, Asensio C, Charollais A, Klein M, Theander-Carrillo C, Juge-Aubry CE, Dayer JM, Nicklin MJ, Meda P, Rohner-Jeanrenaud F, Meier CA (2006) Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 49:387–393

    Article  CAS  PubMed  Google Scholar 

  • Soper DL, Sheville JX, O’Neil SV, Wang Y, Laufersweiler MC, Oppong KA, Wos JA, Ellis CD, Baize MW, Chen JJ, Fancher AN, Lu W, Suchanek MK, Wang RL, Schwecke WP, Cruze CA, Buchalova M, Belkin M, Wireko F, Ritter A, De B, Wang D, Demuth TP Jr (2006) Synthesis and evaluation of novel 8,5-fused bicyclic peptidomimetic compounds as interleukin-1beta converting enzyme (ICE) inhibitors. Bioorg Med Chem 14:7880–7892

    Article  CAS  PubMed  Google Scholar 

  • Soter NA, Austen KF (1976) The diversity of mast cell-derived mediators: implications for acute, subacute, and chronic cutaneous inflammatory disorders. J Invest Dermatol 67(3):313–319

    Google Scholar 

  • Tesch H, König W (1979) Origin and biological role of lipid mediators during inflammation (author’s transl). Immun Infekt 7(5):157–164

    Google Scholar 

  • Trivella DB, Ferreira-Junior JR, Dumoutier L, Renauld JC, Polikarpov I (2010) Structure and function of interleukin-22 and other members of the interleukin-10 family. Cell Mol Life Sci 67:2909–2935

    Article  CAS  PubMed  Google Scholar 

  • Van Snick J (1990) Interleukin-6: an overview. Annu Rev Immunol 8:253–278

    Article  PubMed  Google Scholar 

  • Vezzani A, Balosso S, Maroso M, Zardoni D, Noe F, Ravizza T (2010) ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr Opin Investig Drugs 11:43–50

    CAS  PubMed  Google Scholar 

  • Wagner G, Laufer S (2006) Small molecular anti-cytokine agents. Med Res Rev 26:1–62

    Article  CAS  PubMed  Google Scholar 

  • Wang YS, Zhang Y, Liang H (2010) Role of microRNAs in diabetes and diabetes-associated complications. Sheng Li Ke Xue Jin Zhan 41:133–136

    PubMed  Google Scholar 

  • Waugh J, Perry CM (2005) Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 19:189–202

    Article  CAS  PubMed  Google Scholar 

  • Wu Y, Tai CL, Wei H, He F, Wang Y, Zhao Y, Chen HD (2008) Protective effects of cyclooxygenase-2 inhibitors on narrow-band ultraviolet B-irradiated epidermal Ia+ Langerhans cells and thy-1+ dendritic epidermal T cells in mice. Photochem Photobiol 84:484–488

    Article  CAS  PubMed  Google Scholar 

  • Zhang L, Bertucci AM, Smith KA, Xu L, Datta SK (2007) Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Arthritis Rheum 56:4132–4141

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Madathilkovilakath Haridas .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Bhavya, B.C., Haridas, M. (2017). Anti-inflammatory Molecules: Immune System Mediators. In: Sugathan, S., Pradeep, N., Abdulhameed, S. (eds) Bioresources and Bioprocess in Biotechnology. Springer, Singapore. https://doi.org/10.1007/978-981-10-4284-3_10

Download citation

Publish with us

Policies and ethics